Navigation Links
Pfizer Whistleblower Named Year's Most Influential Person In Business Ethics
Date:12/18/2009

WASHINGTON, Dec. 18 /PRNewswire-USNewswire/ -- John Kopchinski, the whistleblower whom Phillips & Cohen LLP represented in a successful, record-setting "qui tam" case against Pfizer Inc., has been named as the most influential person in business ethics for 2009.

Ethisphere, a think tank that focuses on business ethics, corporate social responsibility, anti-corruption and sustainability, compiles an annual list of the 100 most influential people in business ethics. The group named Kopchinski number one on its 2009 list.

A former sales representative for Pfizer, Kopchinski exposed the company's illegal sales and marketing campaign for the prescription painkiller Bextra for uses and in doses that endangered patients' health and lives. (See http://www.phillipsandcohen.com/CM/NewsSettlements/NewsSettlements531.asp)

Pfizer paid $1.8 billion in September to the government to settle Kopchinski's qui tam lawsuit and a related criminal charge. The company settled four other whistleblower lawsuits at the same time, bringing the total settlement to $2.3 billion. It was the largest healthcare fraud settlement ever and the largest criminal fine ever imposed in the U.S.

"John Kopchinski wasn't seen as a team player and ultimately lost his job at Pfizer," said Erika Kelton, a Washington, DC, attorney with Phillips & Cohen. "But the happy ending to his story and the recognition this honor bestows should give other whistleblowers hope."

Kopchinski "officially turned whistleblowing into big business," said Ethisphere. He received more than $70 million as a reward for the work he and his attorneys did on the Pfizer case. The False Claims Act requires the government to award whistleblowers a percentage of the funds the government recovers as a result of their qui tam cases.

Phillips & Cohen specializes in representing whistleblowers in cases involving fraud against the government, tax matters and securities violations. Cases brought by the firm's attorneys have recovered more than $5.3 billion in civil and criminal penalties for the government. For more information about whistleblowers and qui tam cases, see www.phillipsandcohen.com.

For more information about the Pfizer qui tam case and settlement, see http://www.phillipsandcohen.com/CM/NewsSettlements/NewsSettlements536.asp

SOURCE Phillips & Cohen LLP


'/>"/>
SOURCE Phillips & Cohen LLP
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... 2017 Therapix Biosciences Ltd. (Nasdaq: TRPX), ... the development of cannabinoid-based drugs, today announced that ... at three upcoming scientific and investor conferences in ... Invitational: ...                     Wednesday, June ...
(Date:5/26/2017)... , May 26, 2017  Endo International plc (NASDAQ: ... President and CEO, will represent the Company in a fireside ... Conference on Tuesday, June 13, 2017 at 10:40 a.m. PT ... Terranea Resort in Rancho Palos Verdes, CA. ... the event will be available on the Company,s website at ...
(Date:5/24/2017)... , May 24, 2017  ivWatch LLC ... Equipment Manufacturer (OEM) Board to enable seamless integration ... patient monitoring systems, infusion pumps and other devices. ... will be able to help health care customers ... reduced risks related to IV therapy. ...
Breaking Medicine Technology:
(Date:6/22/2017)... ... June 22, 2017 , ... United Benefit ... welcome Whipple & Company as its newest Partner Firm. Headquartered in Coconut Creek, ... clients’ risk while tailoring optimized benefit packages that strengthen the relationship between employer ...
(Date:6/22/2017)... ... June 22, 2017 , ... Children’s National ... Heart Association (AHA) to launch a Rheumatic Heart Disease Center, with the goal ... of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries and low-income communities ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... environmental excellence. Maryland Recycling Network has awarded the Baltimore VA Medical Center, a ... Government Program Award for its efforts to promote waste reduction and promote recycling. ...
(Date:6/22/2017)... ... ... A June 12 article in The Star offers the advice ... oral hygiene by an aged parent who had recently suffered a series of minor ... steps, including scheduling a dentist visit. Northridge Dental Works, a Los Angeles Area dental ...
(Date:6/20/2017)... Murfreesboro, Tennessee (PRWEB) , ... June 20, 2017 ... ... chronic care services, announced today that Claritas Capital, a Nashville-based private equity firm, ... to accelerate our expansion plans for some time, and Claritas Capital offers the ...
Breaking Medicine News(10 mins):